Can a respiratory stimulant help ventilator patients wean off faster?
NCT ID NCT07637149
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether doxapram, a drug that stimulates breathing, can help adults on mechanical ventilation transition to breathing on their own. Sixty ICU patients ready to wean will receive either doxapram or a placebo during a breathing trial. Researchers will measure diaphragm movement and track whether patients avoid needing a ventilator again within 72 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
doxapram
What this could lead to
If it works, doxapram could help ICU patients come off ventilators faster and avoid needing a breathing tube again.
What could go wrong
This is a small, early-phase study with only 60 patients. Doxapram may not improve weaning success and could cause side effects like jitteriness or high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MECHANICALLY VENTILATED ICU PATIENTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••